Top 5 Contagion® News Articles for the Week of October 29, 2017
NOV 04, 2017 | CONTAGION® EDITORIAL STAFF
#5: How is Pharma Tackling Antibiotic Resistance? Public Health Watch Report
We are entering the “antibiotic apocalypse.”
At least that’s the phrase used by England’s chief medical officer, Sally Davies, DBE, FMedSci, FRS, to describe the current situation regarding the growing problem of resistance. Dr. Davies made the comment in response to findings, initially presented at the American Society of Microbiology’s annual meeting and published in February in the journal Antimicrobial Agents and Chemotherapy(AAC), that bacteria containing the gene MCR-1 confers resistance to the antibiotic colistin.
As the authors of the AAC paper note, colistin is generally considered an “antibiotic of last resort,” and the discovery of the resistance conferred by the MCR-1 gene could mean that routine surgical procedures and hospitalizations would suddenly become fraught with peril due to the increased risk for resistant infections.
Read the rest of the Public Health Watch Report, here.
#4: FDA Clears 3 Antimicrobial Susceptibility Tests to Guide Appropriate Use of Baxdela
This week, Melinta Therapeutics announced that the US Food and Drug Administration (FDA) has cleared 3 antimicrobial susceptibility tests (ASTs) that will help health care practitioners use its new fluoroquinolone Baxdela, appropriately.
Baxdela (delafloxacin) was recently approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, and is available in both tablet, 450 mg, and intravenous, 300 mg, formulations; it can be dosed for 5 to 14 days, twice daily.
The 3 cleared ASTs are: Hardy Diagnostics’ Delafloxacin Antimicrobial Susceptibility Disk (HardyDisk), Liofilchem Delafloxacin MIC Test Strip (MTS), and Thermo Scientific Sensititre MIC System.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512